Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6DDH

Crystal structure of the double mutant (D52N/R367Q) of NT5C2-537X in the active state, Northeast Structural Genomics Target

Summary for 6DDH
Entry DOI10.2210/pdb6ddh/pdb
DescriptorCytosolic purine 5'-nucleotidase, INOSINIC ACID (3 entities in total)
Functional Keywordsstructural genomics, psi-biology, northeast structural genomics consortium, nesg, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight64275.89
Authors
Primary citationDieck, C.L.,Tzoneva, G.,Forouhar, F.,Carpenter, Z.,Ambesi-Impiombato, A.,Sanchez-Martin, M.,Kirschner-Schwabe, R.,Lew, S.,Seetharaman, J.,Tong, L.,Ferrando, A.A.
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Cancer Cell, 34:136-147.e6, 2018
Cited by
PubMed Abstract: Activating mutations in the cytosolic 5'-nucleotidase II gene NT5C2 drive resistance to 6-mercaptopurine in acute lymphoblastic leukemia. Here we demonstrate that constitutively active NT5C2 mutations K359Q and L375F reconfigure the catalytic center for substrate access and catalysis in the absence of allosteric activator. In contrast, most relapse-associated mutations, which involve the arm segment and residues along the surface of the inter-monomeric cavity, disrupt a built-in switch-off mechanism responsible for turning off NT5C2. In addition, we show that the C-terminal acidic tail lost in the Q523X mutation functions to restrain NT5C2 activation. These results uncover dynamic mechanisms of enzyme regulation targeted by chemotherapy resistance-driving NT5C2 mutations, with important implications for the development of NT5C2 inhibitor therapies.
PubMed: 29990496
DOI: 10.1016/j.ccell.2018.06.003
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.35 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon